Advancing first-in-class onco-dermatology therapies that target cancer at its metabolic core.
Phase 2b EMA Study
Ongoing in Advanced Actinic Keratosis (Germany)
Phase 2b FDA Study
Completed in Actinic Keratosis
Shares Publicly Traded
on Xetra & Tradegate (TSG)
7 Global Patent Families
Secured
All 39 patients enrolled; follow-up continues as planned. London, UK, 12 June 2026 – Vidac Pharma Holdings Plc. (XETRA: T9G | ISIN: GB00BM9XQ619 | WKN: A3DTUQ) announces the completion of patient enrollment in the Company's Phase 2B clinical study evaluating VDA-1102.
Strengthens global intellectual property portfolio supporting the Company's novel cancer therapeutics London, UK, 27 May 2026 – Vidac Pharma Holdings Plc. (XETR
Company evaluating strategic expansion into leading European life sciences and innovation ecosystem London, UK, 12 May 2026 – Vidac Pharma Holdings Plc. (XETRA:
